J&J's Spravato Set For EU Launches Soon
Ketamine-Like Antidepressant Backed By CHMP
Executive Summary
If the nasal spray is approved by the European Commission, seven months after getting the green light in the US, Spravato will offer the first new mechanism of action in 30 years to treat major depressive disorder.
You may also be interested in...
Blow For Janssen As England's NICE Rejects Depression Spray Spravato
Uncertainties over clinical and cost effectiveness are behind the health technology assessment body’s recommendation against Spravato's use on the National Health Service.
EMA Prepares Approval Verdict On Beovu, Idhifa, Recarbrio
Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.
J&J Looks To Expand Spravato Label To Suicidal Ideation
The big pharma will seek the new indication later this year based on Phase III data showing a rapid decrease in depression symptoms, but without a significant improvement over placebo in suicidality.